Chevy Chase Trust Holdings LLC Has $21.69 Million Position in Moderna, Inc. (NASDAQ:MRNA)

Chevy Chase Trust Holdings LLC cut its stake in Moderna, Inc. (NASDAQ:MRNA) by 0.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 182,644 shares of the company’s stock after selling 1,647 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Moderna were worth $21,689,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Ogorek Anthony Joseph NY ADV purchased a new position in Moderna in the fourth quarter valued at about $27,000. Cedar Wealth Management LLC lifted its holdings in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the last quarter. Westside Investment Management Inc. bought a new stake in shares of Moderna in the 1st quarter valued at approximately $32,000. Rise Advisors LLC increased its holdings in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares during the last quarter. Finally, Bank & Trust Co bought a new position in Moderna during the second quarter valued at approximately $36,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,296 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total value of $210,561.12. Following the sale, the insider now directly owns 10,623 shares in the company, valued at $1,725,918.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Shannon Thyme Klinger sold 1,296 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total value of $210,561.12. Following the completion of the sale, the insider now directly owns 10,623 shares in the company, valued at $1,725,918.81. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $157.57, for a total value of $2,363,550.00. Following the transaction, the director now owns 1,981,931 shares in the company, valued at approximately $312,292,867.67. The disclosure for this sale can be found here. Insiders sold 366,238 shares of company stock worth $51,819,454 in the last 90 days. 15.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on MRNA shares. UBS Group increased their price target on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Evercore ISI reissued an “in-line” rating and set a $120.00 target price on shares of Moderna in a research report on Thursday, June 27th. The Goldman Sachs Group reduced their price target on Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, August 2nd. Canaccord Genuity Group increased their price objective on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday, May 3rd. Finally, Royal Bank of Canada lowered Moderna from an “outperform” rating to a “sector perform” rating and reduced their target price for the stock from $125.00 to $90.00 in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus price target of $124.07.

Moderna Stock Performance

Moderna stock traded down $3.02 on Tuesday, hitting $86.94. The company’s stock had a trading volume of 2,705,013 shares, compared to its average volume of 4,109,126. The company has a fifty day moving average price of $115.07 and a 200-day moving average price of $113.90. The firm has a market cap of $33.32 billion, a P/E ratio of -5.67 and a beta of 1.67. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The company has a quick ratio of 3.91, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($3.62) earnings per share. On average, equities analysts anticipate that Moderna, Inc. will post -7.46 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.